Feline Blood Transfusion: Compatibility and Monitoring

Bottom line

Choose feline transfusion from the recipient's clinical condition and the deficit being treated, not a universal packed cell volume (PCV) threshold. AB blood typing remains essential; crossmatching addresses additional incompatibility and requires a separate decision. [1] Document that decision, select the product deliberately, and arrange monitoring before administration begins.

Define the deficit before requesting a product

The ISFM guideline considers the cause and speed of anemia, clinical compromise, and continuing blood loss. A cat with peracute hemorrhage may need red-cell support before PCV has fallen. Conversely, a numerical anemia result alone does not settle whether transfusion is indicated. [1]

Record the intended endpoint: support of oxygen-carrying capacity, replacement of coagulation factors, or both. For an actively bleeding patient, the feline epistaxis workup addresses localization and hemostatic investigation; transfusion supports the patient while the cause is assessed.

Packed red cells allow red-cell replacement with less volume than whole blood and are particularly useful when circulatory overload is a concern. Plasma is used for coagulation-factor replacement and does not substitute for red cells in anemia. Product selection must also consider what is available and the recipient's condition. [1]

Separate blood typing from crossmatching

Type donor and recipient before allotransfusion and select AB-compatible blood. Naturally occurring antibodies against AB-system antigens can cause severe incompatibility. Other feline red-cell antigens mean that an AB-compatible result does not exclude every incompatible donor–recipient pairing. [1]

Crossmatching asks whether this recipient's plasma reacts with this donor's cells; it does not replace blood typing or donor infectious-disease screening. ISFM describes first-transfusion crossmatching as controversial but notes recommendations to crossmatch where possible. [1]

Put the available transfusion history, sample identity and compatibility results beside the unit identifier. Resolve discrepancies before the unit reaches the patient. An emergency exception should record why delay was considered more dangerous and who made that decision.

Explain the first-transfusion evidence without overstating it

In a prospective randomized trial, transfusion-naïve anemic cats receiving AB-compatible packed red cells were assigned to crossmatched or non-crossmatched transfusion. The investigators found no significant difference in acute transfusion reactions or dose-adjusted PCV response. Cats too unstable to tolerate the testing delay were excluded. The trial therefore does not answer every emergency scenario or the management of previously transfused cats. [2]

A separate retrospective study documented naturally occurring non-AB incompatibilities and fewer febrile reactions in crossmatched recipients. Crossmatching was not associated with an improved PCV increment or survival. Selection and treatment differences in a retrospective cohort prevent interpreting the association as proof of benefit for every cat. [3]

These findings support an explicit compatibility policy rather than either extreme: treating AB typing as sufficient for every subsequent transfusion, or claiming that first-transfusion crossmatching has a proven survival benefit. Keep the test's purpose and the actual evidence endpoint separate.

Prepare administration and observation together

Before starting, establish the recipient's temperature, cardiovascular findings, respiratory rate and effort, mentation and other relevant baseline observations. ISFM recommends close early observation and continued monitoring during transfusion. Appropriate blood filtration and equipment selection are part of safe administration; a routine intravenous-fluid filter is not interchangeable with a blood filter. [1]

A pre-existing respiratory problem should be documented rather than rediscovered after the unit starts. The feline respiratory-distress workup helps frame that separate assessment. Specify who observes the cat, who can interrupt administration, and where the unit and recipient checks are recorded.

Investigate deterioration before assigning a reaction label

Hall and colleagues' prospective multicenter observational study used standardized reaction definitions. Febrile nonhemolytic reactions predominated, but the authors warn that inconsistent investigation for hemolysis could miss or misclassify acute hemolytic reactions. They also found that some transfusions paused for suspected reactions did not ultimately meet the study's reaction criteria. [4]

New deterioration warrants immediate assessment under the hospital's transfusion-reaction procedure. Recheck identity and compatibility records, evaluate the patient and product, and distinguish a suspected reaction from progression of the underlying illness. Do not let a provisional label substitute for investigation or restart a product solely because fever appears mild.

The same observational study associated older red-cell units and infusion-pump administration with higher odds of febrile nonhemolytic reactions. The authors discuss alternative explanations, device differences and possible statistical error. This is not proof that every infusion pump causes hemolysis. [4] Use a validated delivery system and a defined local blood-bank protocol rather than extrapolating a universal device prohibition.

Afterward, document the product, compatibility testing, administration course, measured response and any suspected reaction. Preserve this record for the next transfusion decision; a satisfactory immediate PCV response is only one part of the outcome.

Frequently Asked Questions

Is there a universal PCV threshold for feline transfusion?

No. ISFM recommends assessing the clinical condition, cause and speed of anemia, and ongoing blood loss rather than using a universal PCV trigger. [1]

Does a compatible AB blood type exclude every incompatibility?

No. Feline non-AB antigens can produce incompatibility despite AB-compatible blood. [1]

Did the randomized first-transfusion trial establish that crossmatching is unnecessary?

No. It found no significant difference in acute reactions or PCV response in the studied transfusion-naïve, AB-typed cats; unstable cats in whom testing would cause a dangerous delay were excluded. [2]

Does retrospective evidence prove crossmatching improves survival?

No. The retrospective study found fewer febrile reactions with crossmatching but no demonstrated improvement in survival or PCV response. [3]

Is plasma a substitute for red cells in an anemic cat?

No. Plasma supplies coagulation factors; red-cell products address deficient oxygen-carrying capacity. [1]

Does fever during transfusion identify a nonhemolytic reaction by itself?

No. Hall and colleagues emphasize investigation for hemolysis because incomplete assessment can misclassify acute hemolytic reactions as febrile nonhemolytic reactions. [4]

Does a reaction-free first transfusion remove the need to reassess compatibility later?

No. Reassess compatibility before a later transfusion rather than treating an earlier uneventful event as permanent assurance.